Bioequivalence Comparison of Two Formulations of Fixed-Dose Combination Glimepiride/Metformin (2/500 mg)Tablets in Healthy Volunteers

Sang-Hoon Jung, Jung-Woo Chae, Byung-Jeong Song, Kwang-Il Kwona, Sang-Hoon Jung, Jung-Woo Chae, Byung-Jeong Song, Kwang-Il Kwona

Abstract

Glimepiride/metformin (2/500 mg) is an oral antihyperglycemic agent for the treatment of type 2 diabetes. A generic glimepiride/metformin (2/500 mg) fixed-dose combination (FDC) tablet was developed recently. This study was designed to collect data for submission to Korean regulatory authorities to allow the marketing of the test formulation. We evaluated the comparative bioavailability and tolerability of the test and reference formulations in healthy male adult volunteers. This single-dose, randomized, double-blind, two-way crossover trial was conducted at Bestian Medical Center in Bucheon, Korea. In total, 40 male Korean volunteers were enrolled. The subjects were randomized to receive an FDC tablet containing the glimepiride/metformin (2/500 mg) test or reference formulation, and pharmacokinetic(PK) parameters were measured. After a 1-week washout period, the other formulation was administered and the PK parameters were measured again. The Cmax and AUCt were determined from blood samples obtained at 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, and 24 h after drug administration. Bioequivalence was considered established if the 90% CIs of the geometric mean ratios(GMRs) of the test-to-reference formulations for Cmax and AUCt were within the predetermined regulatory range of 80-125%. In total, 40 healthy male subjects were enrolled and completed the study (mean [SD] age, 23.2[2.26]years[range, 19-30years];weight, 68.95[8.30]Kg[range, 52.0-87.0 Kg]; and height, 175.4[5.34] cm[range, 164-189 cm]). The GMRs(90% CI) of the glimepiride Cmax and AUCt were 1.006(0.947-1.069) and 1.010(0.953-1.071), respectively. For metformin, the values were 1.019(0.959-1.083) and 1.035(0.989-1.084), respectively. The test and reference formulations had similar PK parameters. The test formulation of glimepiride/metformin (2/500 mg) FDC tablets met the Korean regulatory criteria for bioequivalence.

Keywords: Bioequivalence; Combination drug; Glimepiride; Metformin; Pharmacokinetic properties.

Figures

Figure 1
Figure 1
Structural representation of metformin, glimepiride and glipizide
Figure 2
Figure 2
Mean(SD) plasma concentration-time profiles of glimepiride and metformin after administration 2 formulations of a glimepiride/metformin 2/500 mg FDC tablet

References

    1. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM: a balanced overview. Diabetes Care. 1992;15:318–368.
    1. Stumvoll M, Goldstein BJ, Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet. 2005;365:1333–1346.
    1. Fritsche L, Weigert C, Haring HU, Lehmann R. How insulin receptor substrate proteins regulate the metabolic capacity of the liver implications for health and disease. Curr.Med. Chem. 2008;15:1316–1329.
    1. Kahn SE. The relative contributions of insulin resistance and betacell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia. 2003;46:3–19.
    1. Bjornholm M, Zierath JR. Insulin signal transduction in human skeletal muscle: identifying the defects in type II diabetes. Biochem. Soc. Trans. 2005;33:354–357.
    1. Lin Y, Sun Z. Current views on type 2 diabetes. J. Endocrinol. 2010;204:1–11.
    1. G Schernthaner. Fixed-dose combination therapies in the management of hyperglycaemia in Type 2 diabetes: an opportunity to improve adherence and patient care. Diabet. Med. 2010;27:739–743.
    1. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am. J. Med. 2007;120:713–719.
    1. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA. 2002;287:360–372.
    1. Tosi F, Muggeo M, Brun E, Spiazzi G, Perobelli L, Zanolin E, Gori M, Coppini A, Moghetti P. Combination treatment with metformin and glibenclamide versus single-drug therapies in type 2 diabetes mellitus: a randomized, double-blind, comparative study. Metab.Clin. Exp. 2003;52:862–867.
    1. Garber AJ, Larsen J, Schneider SH, Piper BA, Henry D. Glyburide/Metformin Initial Therapy Study Group. Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes. Diabetes Obes. Metab. 2002;4:201–208.
    1. Garber AJ, Donovan DS Jr, Dandona P, Bruce S, Park JS. Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes. J. Clin. Endocrinol. Metab. 2003;88:3598–3604.
    1. Kramer W, Muller G, Geisen K. Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at beta cells. Horm. Metab. Res. 1996;28:464–468.
    1. Badian M, Korn A, Lehr KH, Malerczyk V, Waldhausl W. Absolute bioavailability of glimepiride (Amaryl) after oral administration. Drug Metabol. Drug Interact. 1994;11:331–339.
    1. Benet LZ. Predicting drug disposition via application of a Biopharmaceutics Drug Disposition Classification System. Basic Clin. Pharmacol. Toxicol. 2010;106:162–167.
    1. McEvoy GK, Livak KG. AHFS drug information. Washinton DC: ASPH; 2002. pp. 3052–3061.
    1. Moses R, Slobodnjuk R, Boyages S, Colagiuri S, Kidson W, Carter J, Donnelly T, Moffitt P, Hopkins H. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 1999;22:119–124.
    1. Kwon KI. Clinical Drug Therapy of Disease. 2nd ed. Seoul: Shinil; 2003. pp. 433–437.
    1. DeFronzo RA, Goodman AM. For The Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N. Engl. J. Med. 1995;333:541–549.
    1. Patterson S, Jones B, editors. Bioequivalence and Statistics in Clinical Pharmacology. Boca Raton : Chapman & Hall/CRC; 2005.
    1. Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, Zdravkovic M, During M, Matthews DR. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD(Liraglutide Effect and Action in Diabetes)-2 study. Diabetes Care. 2009;32:84–90.
    1. Mandal U, Pal TK. Formulation and in-vitro studies of a fixed-dose combination of a bilayer matrix tablet containing metformin HCl as sustained release and glipizide as immediate release. Drug Dev. Ind. Pharm. 2008;34:305–313.
    1. Defang O, Shufang N, Wei L, Hong G, Hui L, Weisan P. In-vitro and in-vivo evaluation of two extended release preparations of combination metformin and glipizide. Drug Dev. Ind. Pharm. 2005;31:677–685.
    1. [The Helsinki Declaration] Assist Inferm. Ric. 2010;29:41–44.
    1. Liu Y, Zhang M, Zhu J, Jia J, Liu Y, Liu G, Li S, Weng L, Yu C. Bioequivalence and pharmacokinetic evaluation of two formulations of glimepiride 2 mg: A single-dose, randomized-sequence, open-label, two-way crossover study in healthy chinese male volunteers. Clin. Ther. 2010;32:959–995.
    1. Al Hawari S, AlGaai E, Yusuf A, Abdelgaleel A, Hammami MM. Bioequivalence study of two metformin formulations. Arzneimittelforschung. 2007;57:192–195.
    1. Sengupta P, Bhaumik U, Ghosh A, Sarkar AK, Chatterjee B, Bose A, Pal TK. LC–MS–MS Development and Validation for Simultaneous Quantitation of Metformin, Glimepiride and Pioglitazone in Human Plasma and Its Application to a Bioequivalence Study. Chromatographia. 2009;69:1243–1250.
    1. Song YK, Maeng JE, Hwang HR, Park JS, Kim BC, Kim JK, Kim CK. Determination of glimepiride in human plasma using semi-microbore high performance liquid chromatography with column-switching. J. Chromatogr. B. 2004;810:143–149.
    1. Najiba N, Idkaideka N, Beshtawia M, Bader M, Admour I, Alam SM, Zaman Q, Dham R. Bioequivalence Evaluation of Two Brands of Metformin 500 mg Tablets (Dialon1 & Glucophage1) – in Healthy Human Volunteers. Biopharm. Drug Dispos. 2002;23:301–306.
    1. Gabrielsson J, Weiner D. Pharmacokinetic and Pharmacodynamic Data Analysis, Concepts and Applications. 4th(eds.) Stockholm Sweden: Swedish Pharmaceutical Press ; 2007. pp. 1–4.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe